SuperworthIronwood Pharmaceuticals EPS IRWD
Diluted earnings per share by quarter and over the last twelve months, from 2010.
- Last 12 months, to Jun 30, 2026
- $0.77
- Latest quarter, Q2 FY26
- $0.31
- +121% on a year earlier
- Fiscal year 2025
- $0.13
Ironwood Pharmaceuticals' earnings per share was $0.77 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was $0.31, up 121% on the same quarter a year before.
Over the five fiscal years to FY2025 it shrank 28% a year on average.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | $0.13 | n/a |
| FY2024 | −$0.01 | n/a |
| FY2023 | −$6.51 | −771% |
| FY2022 | $0.97 | −70% |
| FY2021 | $3.23 | +389% |
| FY2020 | $0.66 | +371% |
| FY2019 | $0.14 | n/a |
| FY2018 | −$1.85 | n/a |
| FY2017 | −$0.80 | n/a |
| FY2016 | −$0.56 | n/a |
| FY2015 | −$1.00 | n/a |
| FY2014 | −$1.39 | n/a |
| FY2013 | −$2.38 | n/a |
| FY2012 | −$0.71 | n/a |
| FY2011 | −$0.66 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | $0.31 | +121% | $0.77 | |
| Q1 FY26 | $0.24 | n/a | $0.60 | |
| Q4 FY25 | −$0.01 | −200% | $0.13 | |
| Q3 FY25 | $0.23 | +1050% | $0.15 | |
| Q2 FY25 | $0.14 | n/a | −$0.06 | |
| Q1 FY25 | −$0.23 | n/a | −$0.21 | |
| Q4 FY24 | $0.01 | n/a | −$0.01 | |
| Q3 FY24 | $0.02 | −78% | −$0.03 | |
| Q2 FY24 | −$0.01 | n/a | $0.04 | |
| Q1 FY24 | −$0.03 | −112% | −$6.79 | |
| Q4 FY23 | −$0.01 | −104% | −$6.51 | |
| Q3 FY23 | $0.09 | −68% | −$6.23 |
Against its peers
Companies in Drug Manufacturers - General nearest Ironwood Pharmaceuticals' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| IRWDIronwood Pharmaceuticals | $0.77 | |
| PBYIPuma Biotechnology | $0.52 | −47% a year |
| ZVRAZevra Therapeutics | $0.93 | |
| CRMDCorMedix | $2.13 | +184% a year |
| ARVNArvinas | $0.16 | |
| COLLCollegium Pharmaceutical | $1.24 | +19% a year |
| ABUSArbutus Biopharma | $0.78 | |
| AMPHAmphastar Pharmaceuticals | $1.70 | −36% a year |
| OMEROmeros | $1.52 | |
| PCRXPacira BioSciences | $0.35 | |
| ANABAnaptysbio | $4.57 | |
| Peer median | $1.08 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Ironwood Pharmaceuticals
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.